Back to News
Market Impact: 0.35
Natera Announces Japan's PMDA Authorization For Signatera In Muscle-Invasive Bladder Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Natera's Signatera test received approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic for muscle-invasive bladder cancer. The authorization supports use of the test to guide treatment decisions, expanding Signatera's regulatory footprint and potential commercial opportunity in Japan.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.48
Ticker Sentiment
NTRA0.72
More News
- How the US midterm elections reflected resistance to data centres
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Bitcoin rebounds to $76,000, but $1.3 billion ETF exodus tests recovery